Isocitrate dehydrogenase (IDH) inhibitors are another type of targeted therapies that target the genetic mutations in isocitrate dehydrogenase genes (IDH1 and IDH2) in acute myeloid leukemia (AML), occurring in up to 30% of AML cases [139]. This evidence concerns the gene IDH3A and acute myeloid leukemia.